| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/22/2001 | CN1309562A Topical compositions comprising opioid analgesic and NMDA antagonist |
| 08/22/2001 | CN1309560A Prevention of migraine recurrence |
| 08/22/2001 | CN1309556A Biodegradable sustained-release alginate gels |
| 08/22/2001 | CN1309555A Incorporation of active substances in carrier matrixes |
| 08/22/2001 | CN1308937A Method for preparing microcapsule |
| 08/21/2001 | US6277979 KIAA0551 polynucleotides and polypeptides use |
| 08/21/2001 | US6277977 cDNA clone HAPOI67 that encodes a human 7-transmembrane receptor |
| 08/21/2001 | US6277965 Amino acid sequence of cysteinyl trna (transfer ribonucleic acid) synthetase from chlamydia; bactericides; bacteriostats; enzyme inhibitors; drug screening; diagnosis; vaccines |
| 08/21/2001 | US6277892 Topical composition comprising sunless tanning agent and high molecular weight crosslinked cationic polymer based on dialkylaminoalkyl (meth)acrylate monomer or its quaternary ammonium or acid addition salt |
| 08/21/2001 | US6277884 Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
| 08/21/2001 | US6277880 Chemical compounds |
| 08/21/2001 | US6277879 Calanolide analogues and methods of their use |
| 08/21/2001 | US6277875 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 08/21/2001 | US6277870 Use |
| 08/21/2001 | US6277869 Pharmaceutical composition |
| 08/21/2001 | US6277855 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| 08/21/2001 | US6277846 Use of platelet activating factor antagonists as anti-pruritic agents |
| 08/21/2001 | US6277839 Antiinflammatory agents, antipyretics, analgesics; side effect reduction |
| 08/21/2001 | US6277836 Methods and compositions for treating inflammatory bowel disease |
| 08/21/2001 | US6277835 Method of tumor treatment |
| 08/21/2001 | US6277831 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use |
| 08/21/2001 | US6277829 Dissolving azithromycin in solution of polybasic phosphate and citric acid; treatment of conjunctivitis, keratitis and blepharitis |
| 08/21/2001 | US6277620 Polypeptide for the prevention of bacterial infection; bactericides; for vaccine development |
| 08/21/2001 | US6277613 TRF1 binding protein, methods of use thereof |
| 08/21/2001 | US6277585 Vertebrate unc-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins; use in diagnosis, therapy and in the biopharmaceutical industry |
| 08/21/2001 | US6277575 Process aimed at evidencing the state of a malignant cell |
| 08/21/2001 | US6277417 (a) protein, (b) carbohydrates, (c) fatty acids, and (d) from about 0.1% to about 4.0% by weight of the carotenoid astaxanthin; prevent and treat benign prostate hyperplasia (bph) and prostate cancer in human males. |
| 08/21/2001 | US6277401 Drug delivery device |
| 08/21/2001 | US6277387 Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF αantagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained |
| 08/21/2001 | US6277384 The amount of opioid antagonist included in the combination product provides at least a mildly negative, ?aversive? experience in physically dependent addicts (e.g., precipitated abstinence syndrome). |
| 08/21/2001 | US6277373 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase |
| 08/21/2001 | US6277372 Porcine ventral mesencephalic cells obtained from an embryonic pig of between ages 24 and 30 of gestation from embryonic connective tissue; |
| 08/21/2001 | US6277366 Noncrosslinked quaternized aminoalkyl acrylate anion exchange resins, antilipemic agent |
| 08/21/2001 | US6277365 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 08/21/2001 | CA2294595C Inhibiting bone resorption |
| 08/16/2001 | WO2001059153A2 Method for identifying substances which modulate the activity of hyperpolarisation-activated cation channels |
| 08/16/2001 | WO2001059133A1 Larynx carcinoma-associated protein larcap-1 |
| 08/16/2001 | WO2001059127A2 Drug metabolizing enzymes |
| 08/16/2001 | WO2001059120A2 Il-17 like molecules and uses thereof |
| 08/16/2001 | WO2001059103A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 08/16/2001 | WO2001059084A1 Protein c derivatives |
| 08/16/2001 | WO2001059072A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 08/16/2001 | WO2001058956A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | WO2001058951A2 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/16/2001 | WO2001058949A2 Heterologous polypeptide of the tnf family |
| 08/16/2001 | WO2001058945A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | WO2001058927A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 08/16/2001 | WO2001058918A2 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 08/16/2001 | WO2001058916A2 Antibodies to ccr5 |
| 08/16/2001 | WO2001058915A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/16/2001 | WO2001058910A2 Lipid-based drug delivery systems |
| 08/16/2001 | WO2001058869A2 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 08/16/2001 | WO2001058491A1 Drug comprising combination |
| 08/16/2001 | WO2001058484A2 Novel uses of mammalian ccr8 receptors and related reagents |
| 08/16/2001 | WO2001058473A1 Method of treating or inhibiting cellular injury or cell death |
| 08/16/2001 | WO2001058472A2 Botulinum toxin pharmaceutical compositions |
| 08/16/2001 | WO2001058470A2 Methods for enhancing the bioavailability of a drug |
| 08/16/2001 | WO2001058469A1 Methods for treating glaucoma |
| 08/16/2001 | WO2001058466A1 Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria |
| 08/16/2001 | WO2001058460A1 Isolation and transplantation of retinal stem cells |
| 08/16/2001 | WO2001058458A1 Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 08/16/2001 | WO2001058455A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 08/16/2001 | WO2001058454A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| 08/16/2001 | WO2001058451A1 Tamper-resistant oral opioid agonist formulations |
| 08/16/2001 | WO2001058450A2 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 08/16/2001 | WO2001058447A1 Controlled-release compositions containing opioid agonist and antagonist |
| 08/16/2001 | WO2001058444A1 Use of cyp1b1 inhibitors for treating cancer |
| 08/16/2001 | WO2001058441A1 Method and compositions for treating an inflammatory disease |
| 08/16/2001 | WO2001058438A1 Ophthalmic use of alpha adrenergic blocking agents |
| 08/16/2001 | WO2001058423A1 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases |
| 08/16/2001 | WO2001058351A1 Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 08/16/2001 | WO2001058241A2 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 08/16/2001 | WO2001058240A2 Photodynamic therapy for treating conditions of the eye |
| 08/16/2001 | WO2001023550A3 Pca3 messenger rna species in benign and malignant prostate tissues |
| 08/16/2001 | WO2001012172B1 Treatment of metastatic disease |
| 08/16/2001 | WO2001010429A3 Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 08/16/2001 | WO2001004354A3 Use of ras inhibitors of inhibiting muscle atrophy |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |
| 08/16/2001 | WO2000076500A8 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 08/16/2001 | WO2000066106A3 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 08/16/2001 | WO2000057866A3 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 08/16/2001 | US20010014698 Method for preventing and treating alcoholism |
| 08/16/2001 | US20010014685 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 08/16/2001 | US20010014678 Using mixture of a nicotine receptor antagonist and antidepressant and,or anxiolytic agent |
| 08/16/2001 | US20010014670 Treating chlamydia infections of central nervous system in mammals/humans not exhibiting symptoms of multiple sclerosis or meningoencephalitis via administering antibiotic; ELISA kits |
| 08/16/2001 | US20010014664 Viscosity; biodegradability; fibroblast growth factor |
| 08/16/2001 | US20010014342 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| 08/16/2001 | EP1143946A3 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 08/16/2001 | EP1123922A2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 08/16/2001 | EP1123717A2 Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
| 08/16/2001 | EP1123509A2 Methods of diagnosing or prognosing alzheimer's disease |
| 08/16/2001 | EP1123405A1 Materials and methods involving conditional aggregation domains |
| 08/16/2001 | EP1123395A2 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same |
| 08/16/2001 | EP1123388A1 Transgenic c. elegans as a model organism for research into alzheimer's disease |
| 08/16/2001 | EP1123385A2 Human proteins involved in endoplasmic reticulum protein degradation |
| 08/16/2001 | EP1123312A2 Human rna binding proteins |
| 08/16/2001 | EP1123283A1 Thiazole-derivatives |